Table 3.

Autoantibody expression according to cGVHD NIH global severity and activity

Characteristics	Autoantibody*					ANA*
	Positive (n=25)	Negative (n=9)	OR	95% CI	P	Positive (n=19)	Negative (n=15)	OR	95% CI	P
cGVHD severity at enrollment
Mild	5 (20.0)	0 (0.0)	1.250	1.028–1.521	0.146	4 (21.1)	1 (6.7)	3.730	0.371–37.58	0.240
Moderate	11 (44.0)	4 (44.4)	0.982	0.212–4.553	0.982	9 (47.4)	6 (40.0)	1.350	0.343–5.315	0.667
Severe	9 (36.0)	5 (55.6)	0.450	0.096–2.120	0.307	6 (31.5)	8 (53.3)	0.404	0.099–1.640	0.201
cGVHD activity
Active	17 (68.0)	6 (66.7)	1.063	0.210–5.737	0.942	12 (63.2)	11 (73.3)	0.623	0.142–2.727	0.529
Non-active	8 (32.0)	3 (33.3)				7 (36.8)	4 (26.7)
Characteristics	Anti-Ro/SS-A 52 kDa*
	Positive (n=6)	Negative (n=28)	OR	95% CI	P
cGVHD severity at enrollment
Mild	2 (33.3)	3 (10.7)	4.167	0.522–33.200	0.162
Moderate	3 (50.0)	11 (39.3)	1.545	0.263–9.082	0.628
Severe	1 (16.7)	14 (50.0)	0.200	0.021–1.930	0.136
cGVHD activity
Active	3 (50.0)	20 (71.4)	0.400	0.066–2.415	0.309
Non-active	3 (50.0)	8 (28.6)

^*Data are expressed as number (percentage). cGVHD, chronic graft-versus-host disease; NIH, National Institutes of Health; ANA, anti-mitochondrial antibody; OR, odds ratio; CI, confidence interval